TEMPUS AI, INC. CLASS A COMMON STOCK

NASDAQ: TEM (Tempus AI, Inc.)

Last update: 13 hours ago

47.10

-2.79 (-5.59%)

Previous Close 49.89
Open 45.41
Volume 2,519,106
Avg. Volume (3M) 13,627,156
Market Cap 8,111,231,488
Price / Sales 11.65
Price / Book 152.50
52 Weeks Range
22.89 (-51%) — 91.45 (94%)
Earnings Date 13 Jan 2025
Profit Margin -101.79%
Operating Margin (TTM) -25.33%
Diluted EPS (TTM) -6.23
Quarterly Revenue Growth (YOY) 35.80%
Total Debt/Equity (MRQ) 830.85%
Current Ratio (MRQ) 2.29
Operating Cash Flow (TTM) -189.04 M
Levered Free Cash Flow (TTM) 82.42 M
Return on Assets (TTM) -57.96%

Market Trend

Short Term Medium Term
Industry Health Information Services (US) Mixed Mixed
Health Information Services (Global) Mixed Mixed
Stock Tempus AI, Inc. Bearish -

AIStockmoo Score

-0.1
Analyst Consensus 1.0
Insider Activity -1.5
Price Volatility 1.0
Technical Moving Averages 1.0
Technical Oscillators -2.0
Average -0.10

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TEM 8 B - - 152.50
HQY 8 B - 81.07 3.69
WAY 7 B - - 2.35
RCM 6 B - - 2.14
PRVA 3 B - 215.18 4.35
WGS 3 B - - 11.76

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Sector Healthcare
Industry Health Information Services
Investment Style Small Growth
% Held by Insiders 47.67%
% Held by Institutions 34.21%

Ownership

Name Date Shares Held
Ark Investment Management Llc 31 Dec 2024 5,519,644
Softbank Group Corp. 31 Dec 2024 5,405,406
Nea Management Company, Llc 31 Dec 2024 5,385,979
Revolution Growth Management Company, Inc. 31 Dec 2024 3,467,565
Nikko Asset Management Americas, Inc. 31 Dec 2024 3,239,093
Neuberger Berman Group Llc 31 Dec 2024 1,615,414
Frontier Capital Management Co Llc 31 Dec 2024 943,718
Mariner, Llc 31 Dec 2024 923,786
52 Weeks Range
22.89 (-51%) — 91.45 (94%)
Price Target Range
52.00 (10%) — 74.00 (57%)
High 74.00 (TD Cowen, 57.11%) Buy
Median 60.00 (27.39%)
Low 52.00 (Loop Capital, 10.40%) Buy
Average 60.86 (29.21%)
Total 4 Buy, 3 Hold
Avg. Price @ Call 53.10
Firm Date Target Price Call Price @ Call
Morgan Stanley 06 Mar 2025 60.00 (27.39%) Buy 48.86
Piper Sandler 04 Mar 2025 55.00 (16.77%) Hold 52.73
B of A Securities 03 Mar 2025 60.00 (27.39%) Hold 50.93
JP Morgan 25 Feb 2025 55.00 (16.77%) Hold 59.10
Needham 25 Feb 2025 70.00 (48.62%) Buy 59.10
14 Jan 2025 56.00 (18.90%) Buy 31.83
TD Cowen 05 Feb 2025 74.00 (57.11%) Buy 69.18
Loop Capital 14 Jan 2025 52.00 (10.40%) Buy 31.83
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
POLOVIN ANDREW - 51.35 -3,076 -157,953
Aggregate Net Quantity -3,076
Aggregate Net Value ($) -157,953
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 51.35
Name Holder Date Type Quantity Price Value ($)
POLOVIN ANDREW Officer 21 Mar 2025 Automatic sell (-) 3,076 51.35 157,953
Date Type Details
29 Mar 2025 Announcement Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
26 Mar 2025 Announcement Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
11 Mar 2025 Announcement Tempus Announces Acquisition of Deep 6 AI
24 Feb 2025 Announcement Tempus Reports Fourth Quarter and Full Year 2024 Results
19 Feb 2025 Announcement Tempus to Present at TD Cowen's 45th Annual Health Care Conference
18 Feb 2025 Announcement Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference
18 Feb 2025 Announcement Ares Management Upsizes Tempus Debt Facilities to $560 Million
13 Feb 2025 Announcement Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
11 Feb 2025 Announcement Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24
11 Feb 2025 Announcement Artificial Intelligence (AI) Influence on Healthcare Market Expected to Generate Revenues of $610 Billion By 2034
03 Feb 2025 Announcement Tempus Completes Acquisition of Ambry Genetics
21 Jan 2025 Announcement Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
15 Jan 2025 Announcement Tempus Announces the National Launch of FDA-Approved xT CDx Test
14 Jan 2025 Announcement Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care
13 Jan 2025 Announcement Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH
13 Jan 2025 Announcement Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results
08 Jan 2025 Announcement Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
07 Jan 2025 Announcement Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria